|
EMBARGOED
UNTIL OCTOBER 25, 2000,
11 a.m. (EST) |
Contact:
Jennifer Passantino
(732) 382-5912
Fred Lake
Cooney/Waters Group
(212) 886-2200
|
U.S. SURGEON GENERAL TEAMS WITH MEDICAL
GROUPS TO URGE PRIORITY INFLUENZA & PNEUMOCOCCAL VACCINATION
FOR HIGH-RISK GROUPS
Urgent Call on Health
Care Professionals to Responsibly Administer Influenza
Shots and to Vaccinate Against Pneumococcal Disease
WASHINGTON, D.C. - OCTOBER
25, 2000 - U.S.
Surgeon General David Satcher, M.D., Ph.D., and representatives
of leading medical groups joined today to urge priority
vaccination of individuals at high risk for serious complications
from influenza and pneumococcal infection. Although a
delay in delivery of this year's influenza vaccine supply
is anticipated, vaccine production and distribution will
continue for longer than usual and vaccine will be available
through December and later. "Healthy" individuals should
plan to get their influenza shot in December.
"We are here today to ask
the nation's physicians, nurses and other healthcare providers
to first immunize those most at risk-the elderly and chronically
ill-for influenza, and at the same time to ensure these
groups are vaccinated against pneumococcal disease," said
Dr. Satcher at a press conference convened by the National
Foundation for Infectious Diseases (NFID) and the National
Coalition for Adult Immunization (NCAI).
Joining the surgeon general
at the press conference were representatives of the American
College of Physicians-American Society of Internal Medicine
(ACP-ASIM), Health Care Financing Administration (HCFA),
National Coalition for Adult Immunization (NCAI), National
Foundation for Infectious Diseases (NFID), National Medical
Association (NMA) and U.S. Centers for Disease Control
and Prevention (CDC).
"Bringing the surgeon general
and these key medical groups together underscores the
critical importance of adult vaccination in this country,
especially immunization to prevent influenza and pneumococcal
disease, which claims thousands of lives each year," said
William J. Martone, M.D., NFID's senior executive director.
Influenza annually results
in an average of over 20,000 deaths nationwide and over
110,000 hospitalizations. Pneumococcal disease claims
over 12,000 lives each year in the U.S.
New Influenza Shot Recommendations
Issued
Influenza Vaccine
Keiji Fukuda, M.D., M.P.H.,
epidemiology section chief of CDC's influenza branch,
explained the newly issued, updated recommendations developed
for the 2000-01 influenza season by the CDC's advisory
committee on immunization practices (ACIP). These recommendations
were issued in response to influenza vaccine delivery
delays this year.
"As influenza vaccine first
becomes available through November, vaccination programs
should focus on persons at greatest risk for complications
associated with influenza, including those 65 and over
and those with chronic illnesses, and on health care workers
who have contact with these individuals," said Dr. Fukuda.
Vaccination among high-risk
groups should continue into December and later as long
as influenza vaccine is available. Those at high risk
for complications from influenza are:
- Persons aged 65 or older
- Residents of nursing
homes and other facilities housing persons with chronic
illness
- Children and adults with
chronic pulmonary and cardiovascular disorders, including
asthma
- Children and adults who
have required regular medical follow-up because of chronic
metabolic diseases, including diabetes, renal dysfunction,
hemoglobinpathies or immunosuppression
- Persons aged six months
to 18 years who are receiving long-term aspirin therapy
- Pregnant women in the
second or third trimester of prgnancy during the influenza
season
The CDC also recommends
that mass vaccination campaigns be postponed until later
in the season and held as vaccine becomes available. The
purpose for delaying these campaigns is to minimize the
number of campaigns that are cancelled from lack of vaccine.
Special efforts should be made in December and later to
immunize persons 50-64 years of age who are not at high
risk and are not household contacts of high-risk persons.
During the past 18 influenza
seasons, activity peaked during January through March
in 14 of the seasons. It takes approximately two weeks
after vaccination to develop antibodies against the influenza
to provide protection. "Even with the supply delays, it's
most likely that most people who want to protect themselves
will be able to get vaccine before flu activity peaks,"
said Fukuda.
Pneumococcal Vaccine
CDC also recommends many
of these same high-risk groups be vaccinated against pneumococcal
disease. "Assuring pneumococcal vaccination of high-risk
persons early in the season will provide substantial protection
against the potentially deadly disease," said Kristin
Nichol, M.D., M.P.H., chief of medicine service at VA
Medical Center in Minneapolis, Minnesota.
Pneumococcal vaccine can
be administered at any time of the year, but in adults
it is given most often at the same time as the influenza
vaccine in early to mid-fall. ACIP's new recommendations
stress that pneumococcal vaccine be administered even
if influenza vaccine is not yet available. The ACIP recommendations
also call on providers to emphasize that pneumococcal
vaccination is not a substitute for influenza vaccination
and that patients need to return for influenza vaccine
when it is available in their communities.
Pneumococcal vaccine is
generally given once in a lifetime to those who are vaccinated
at age 65 and older. Any individual who cannot recall
being vaccinated against pneumococcal disease can be safely
revaccinated. Adults who are vaccinated before age 65
or who have certain other chronic conditions may need
to be revaccinated after five years.
"Medicare beneficiaries
are in the high-risk group who need priority vaccination,"
said Jeffrey Kang, M.D., M.P.H., director of the office
of clinical standards and quality, HCFA. "They must not
be discouraged by reports of vaccine delays and should
get their vaccinations now. But they also should remember,
it's better to get their shots late than not to get them
at all."
Influenza and pneumococcal
vaccinations are reimbursable by Medicare Part B.
Disparity in Vaccination
Rates Continues
Along with urging the elderly
and chronically ill to get vaccinated early, the medical
groups called attention to disparities in vaccination
rates-two out of three minority adults aged 65 and older
have not been vaccinated against pneumococcal disease.
"The risk for contracting
pneumococcal disease and influenza among African Americans
and Hispanics older than 65 years of age, and especially
those who have chronic medical conditions, is an ever-present
threat," said Bonnie Word, M.D., representing the NMA.
"African Americans, in particular, appear to be at increased
risk for acquiring pneumococcal disease, and the reasons
for this are not fully understood. An additional factor
that compounds this situation for both African Americans
and Hispanics includes lower levels of vaccination when
compared to other populations."
Also at the press conference,
the American College of Physicians-American Society of
Internal Medicine (ACP-ASIM) announced an initiative encouraging
general internists to improve adult vaccination rates,
including influenza and pneumococcal disease. According
to Sandra Adamson Fryhofer, M.D., F.A.C.P., president
of ACP-ASIM, the three-year initiative will be comprised
of physician education primarily for the organization's
115,000 members, including distribution of practice management
tools to help internists incorporate immunization into
office systems.
Founded in 1973, NFID is
a non-profit organization dedicated to public and professional
educational programs about, and in support of, research
into causes, treatment and prevention of infectious diseases.
NCAI is a network of more
than 100 organizations dedicated to promoting adult immunization
primarily through educational and motivational activities.
The coalition was formed in 1988 to make the most efficient
use of public and private resources to achieve national
goals in adult immunization.
###
This press conference is
supported, in part, by unrestricted educational grants
to the National Foundation for Infectious Diseases and
the National Coalition for Adult Immunization by Aventis
Pasteur, Aviron, Health Care Financing Administration,
Merck Vaccine Division and Wyeth Lederle Vaccines and
Pediatrics.
|